Western Section AUA MAUI 2014

Zytiga® + Low-Dose Predisone Lower PSA Levels in MO-CRPC Patients

Maui—In the IMAAGEN  (Impact of Abiraterone Acetate in Prostate Specific Antigen) core study, patients with non-metastatic castration-resistant prostate cancer (MO-CRPC) had statistically significant reductions in prostate-specific antigen (PSA) levels at 6 months with a therapy regimen of abiraterone acetate (Zytiga®) plus prednisone (5 mg twice daily). The primary end point was the proportion of patients with a ≥50% reduction in ... Read More »

Prostate Cancer at the Western Section AUA Maui 2014

On October 29, the Prostate Cancer Session will include a State of the Art Lecture from Leonard Marks, MD, from UCLA. Dr. Marks is a professor of urology at the David Geffen School of Medicine at UCLA. He was founder and medical director of Urological Sciences Research Foundation, a California non-profit organization (501c3), from its inception in 1992 through year-end 2008, ... Read More »